Skip to main
BHST

BioHarvest Sciences (BHST) Stock Forecast & Price Target

BioHarvest Sciences (BHST) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BioHarvest Sciences Inc demonstrated significant financial growth, achieving record revenues of $6.5 million in the third quarter of 2024, which represents a substantial year-over-year increase of 102%. The company’s robust performance is largely attributed to its flagship nutraceutical product VINIA, highlighting the strong market demand for its innovative health and wellness offerings. Furthermore, favorable market trends in both the pharmaceutical and cosmetics contract development and manufacturing organization (CDMO) sectors, which are projected to experience considerable growth in the coming years, position BioHarvest’s proprietary botanical synthesis technology favorably within these expanding markets.

Bears say

BioHarvest Sciences Inc. faces significant operational risks stemming from potential difficulties in retaining or replacing key management personnel, which could compromise the company’s efficiency and growth potential. Additionally, the company's reliance on consumer acceptance of new products and its ability to secure contractual agreements with Contract Development and Manufacturing Organizations (CDMOs) raises concerns about revenue generation amidst competitive pressures. Furthermore, challenges in maintaining its intellectual property protections and quality management processes could exacerbate financial vulnerabilities, contributing to a pessimistic outlook regarding its market position and overall financial performance.

BioHarvest Sciences (BHST) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioHarvest Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioHarvest Sciences (BHST) Forecast

Analysts have given BioHarvest Sciences (BHST) a Strong Buy based on their latest research and market trends.

According to 2 analysts, BioHarvest Sciences (BHST) has a Strong Buy consensus rating as of Mar 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioHarvest Sciences (BHST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.